Background
Methods
Subjects
N = 623 | N = 258 (eGFR > =90 ml/min/1.73 m2) | |
---|---|---|
Age (years) | 33.2 ± 0.5 | 28.8 ± 0.6 |
Male/Female (N) | 342/281 | 120/138 |
BMI (kg/m2) | 24.8 ± 0.3 | 22.9 ± 0.6 |
SBP (mmHg) | 118.7 ± 0.7 | 115 ± 1.1 |
DBP (mmHg) | 74.8 ± 0.6 | 72.6 ± 1.0 |
eGFR (ml/min/1.73 m2) | 84.2 ± 1.4 | 112.9 ± 1.8 |
pCr (μmol/L) | 108.0 ± 3.0 | 72.8 ± 0.8 |
pUA (μmol/L) | 374.3 ± 4.4 | 338.2 ± 6.7 |
Hyperuricemia (Y/N) (%) | 51.5/48.5 | 37.9/62.1 |
TC (mmol/L) | 4.9 ± 0.1 | 4.7 ± 0.1 |
TG (mmo/L) | 1.5 (1.0-2.3) | 1.4 (0.8-2.2) |
pNa+(mmol/L) | 140.4 ± 0.2 | 139.8 ± 0.2 |
UP (g/24 h) | 1.4 (0.7-1.6) | 1.3 (0.6-2.3) |
M0/1 (%) | 49/51 | 54/46 |
E0/1 (%) | 69/31 | 69/31 |
S0/1 (%) | 53/47 | 61/39 |
T0/1/2 (%) | 79/10/11 | 95/3/2 |
Beijing score [16] | ||
T 0/1/2/3/4 (%) | 7/53/19/10/11 | 13/68/14/3/2 |
Medicine (%) | ||
Allopurinol | 0 | 0 |
Benzbromarone | 0 | 0 |
Diuretics | 10 | 0 |
Losartan | N/A | N/A |
ACEi + ARB | 42 | 42 |
Evaluation of renal pathological changes
Statistical analyses
Results
General data
Plasma uric acid levels associated with tubular atrophy and interstitial fibrosis
The whole cohort | Subgroup | (eGFR > =90 ml/min/1.73 m2) | P | ||
---|---|---|---|---|---|
PUA (μmol/L) | P | PUA (μmol/L) | |||
Oxford score
| |||||
T0 (N = 494) | 359.2+/−4.8 | T0 (N = 246) | 335.9+/−6.9 | ||
T1 (N = 59) | 411.9+/−13.8 | 0.012 | T1 (N = 8) | 363.4+/−35.8 | 0.256 |
T2 (N = 70) | 449.1+/−12.8 | T2 (N = 4) | 416.7+/−53.7 | ||
Tadj_Ox
| |||||
Tadj_Ox0
|
359.2+/−4.8
|
Tadj_Ox0 (N = 246)
|
335.9+/−6.9
| ||
(N = 494)
| |||||
Tadj_Ox1
|
432.1+/−9.4
|
1.5*10
-11
|
Tadj_Ox1 (N = 12)
|
349.8+/−2.8
|
0.150
|
(N = 129)
| |||||
Beijing score
| |||||
T0 (N = 46) | 340.9+/−15.5 | T0 (N = 34) | 335.9+/−18.3 | ||
T1 (N = 332) | 351.9+/−5.8 | T1 (N = 175) | 328.5+/−8.1 | ||
T2 (N = 118) | 387.0+/−9.7 | 4.8*10-4
| T2 (N = 37) | 371.8+/−17.6 | 3.4*10-5
|
T3 (N = 57) | 413.7+/−13.9 | T3 (N = 8) | 363.8+/−37.8 | ||
T4 (N = 70) | 449.1+/−12.6 | T4 (N = 4) | 416.7+/−53.7 | ||
Tadj_Bj
| |||||
Tadj_Bj0
|
350.5+/−5.5
|
Tadj_Bj0 (N = 209)
|
329.7+/−7.4
| ||
(N = 378)
| |||||
Tadj_Bj1
|
411.0+/−6.8
|
0.004
|
Tadj_Bj1 (N = 49)
|
374.2+/−15.2
|
2.3*10
-4
|
(N = 245)
|
Hyperuricemia as a clinical marker of tubular atrophy/interstitial fibrosis
T Oxford score | Tadj_Ox | T Beijing score | Tadj_Bj | GFR | |
---|---|---|---|---|---|
The whole cohort (N = 623)
| |||||
GFR
| −0.473 | −0.425 | −0.513 | −0.451 | |
p
| <0.001 | <0.001 | <0.001 | <0.001 | |
PUA
| 0.262 | 0.257 | 0.284 | 0.261 | −0.371 |
p
| <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Subgroup with eGFR > =90 ml/min
/
1.73 m
2
(N = 258)
| |||||
GFR
| −0.082 | 0.031 | −0.002 | −0.031 | |
p
| 0.187 | 0.625 | 0.979 | 0.618 | |
PUA
| 0.102 | 0.052 | 0.133 | 0.162 | −0.160 |
p
| 0.104 | 0.405 | 0.032 | 0.009 | 0.010 |
Subgroup with eGFR < 90 ml/min
/
1.73 m
2
(N = 365)
| |||||
GFR
| −0.490 | −0.503 | −0.493 | −0.378 | |
p
| <0.001 | <0.001 | <0.001 | <0.001 | |
PUA
| 0.234 | 0.240 | 0.243 | 0.199 | −0.374 |
p
| <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Predictors | OR | 95%C.I. | P | |
---|---|---|---|---|
The whole cohort (N = 623)
| ||||
eGFR
| 0.968 | 0.961-0.975 | <0.001 | |
HUA
| 1.585 | 1.091-2.303 | 0.016 | |
Subgroup with eGFR > =90 ml/min/1.73 m
2
(N = 258)
| ||||
HUA
| 2.097 | 1.112-3.957 | 0.022 | |
Subgroup with eGFR < 90 ml/min/1.73 m
2
(N = 365)
| ||||
eGFR
| 0.9578 | 0.944-0.969 | <0.001 |
Sensitivity | Specificity | P (Chi-square) | P (Exact) | |
---|---|---|---|---|
The whole cohort
| ||||
HUA
| 62.0% | 60.3% | 4.9*10-8
| 5.5*10-8
|
The subgroup with normal eGFR (> = 90 ml/min/1.73 m
2
)
| ||||
HUA
| 53% | 65.1% | 0.016 | 0.022 |